Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Iberdomide |
Synonyms | |
Therapy Description |
Iberdomide (CC-220) binds to the ubiquitin E3 ligase complex member Cereblon (CRBN), which may lead to increased ubiquitination and degradation of transcription factors, resulting in decreased B-cell proliferation (PMID: 29945920, PMID: 28848067, PMID: 31719682). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Iberdomide | CC220|CC-220|CC 220 | Iberdomide (CC-220) binds to the ubiquitin E3 ligase complex member Cereblon (CRBN), which may lead to increased ubiquitination and degradation of transcription factors, resulting in decreased B-cell proliferation (PMID: 29945920, PMID: 28848067, PMID: 31719682). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04776395 | Phase II | Iberdomide Dexamethasone + Iberdomide | Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma | Recruiting | USA | 0 |
NCT02773030 | Phase Ib/II | Iberdomide Dexamethasone + Iberdomide Daratumumab + Dexamethasone + Iberdomide Bortezomib + Dexamethasone + Iberdomide | A Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM) | Active, not recruiting | USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CAN | AUS | 1 |
NCT05354557 | Phase II | Iberdomide | Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT) | Recruiting | USA | 0 |
NCT05827016 | Phase III | Lenalidomide Iberdomide | A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | Recruiting | USA | TUR | SWE | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 11 |
NCT04564703 | Phase II | Iberdomide | Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients | Active, not recruiting | NLD | ITA | GRC | FRA | 0 |
NCT05177536 | Phase II | Iberdomide | Iberdomide Maintenance Therapy in Patients With Multiple Myeloma | Recruiting | USA | 0 |
NCT04464798 | Phase I | Iberdomide Iberdomide + Obinutuzumab Iberdomide + Rituximab | A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas | Active, not recruiting | USA | ITA | FRA | DEU | 2 |
NCT06216158 | Phase III | Iberdomide Iberdomide + Isatuximab Dexamethasone | Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma | Recruiting | DEU | 0 |
NCT05896228 | Phase II | Iberdomide Carfilzomib + Daratumumab + Dexamethasone + Iberdomide | Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma (Iber-KDd) | Recruiting | USA | 0 |
NCT06179888 | Phase II | Iberdomide | Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma | Recruiting | USA | 0 |